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Abstract
Cluster headache is characterized by unilateral attacks of severe pain accompanied by cranial autonomic features.
Apart from these there are also sleep-related complaints and strong chronobiological features. The interaction
between sleep and headache is complex at any level and evidence suggests that it may be of critical importance in
our understanding of primary headache disorders. In cluster headache several interactions between sleep and the
severe pain attacks have already been proposed. Supported by endocrinological and radiological findings as well as
the chronobiological features, predominant theories revolve around central pathology of the hypothalamus. We
aimed to investigate the clinical presentation of chronobiological features, the presence of concurrent sleep
disorders and the relationship with particular sleep phases or phenomena, the possible role of hypocretin as well as
the possible involvement of cardiac autonomic control. We conducted a questionnaire survey on 275 cluster
headache patients and 145 controls as well an in-patient sleep study including 40 CH-patients and 25 healthy
controls. The findings include: A distinct circannual connection between cluster occurrence and the amount of
daylight, substantially poorer sleep quality in patients compared to controls which was present not only inside the
clusters but also outside, affected REM-sleep in patients without a particular temporal connection to nocturnal
attacks, equal prevalence of sleep apnea in both patient and control groups, reduced levels of hypocretin-1 in the
cerebrospinal fluid of patients and finally a blunted response to the change from supine to tilted position in the
head-up tilt table test indicating a weakened sympathoexcitatory or stronger parasympathetic drive. Overall, these
findings support a theory of involvement of dysregulation in hypothalamic and brainstem nuclei in cluster
headache pathology. Further, it is made plausible that the headache attacks are but one aspect of a more complex
syndrome of central dysregulation manifesting as sleep-related complaints, sub-clinical autonomic dysregulation
and of course the severe attacks of unilateral headache. Future endeavors should focus on pathological changes
which persist in the attack-free periods but also heed the possibility of long-lived, cluster-induced pathology.
Introduction
One of the earliest descriptions of cluster headache
(CH) in medical literature is provided by 17th century
Dutch surgeon and mayor of Amsterdam Nicolaes
Tulp (Famously depicted in Rembrandt’s The Anatomy
Lesson of Dr Nicolaes Tulp.) [1]:
“. . . in the beginning of the summer season, [Isaak van
Halmaal] was afflicted with a very severe headache, oc-
curring and disappearing daily on fixed hours, with such
an intensity that he often assured me that he could not
bear the pain anymore or he would succumb shortly.
For rarely it lasted longer than two hours. And the rest
of the day there was no fever, nor indisposition of the
urine, nor any infirmity of the pulse. But this recurring
pain lasted until the fourteenth day . . .”
There can be little doubt that the patient described
was suffering from arguably the most painful condition
known in medicine [2]. With its stereotypical presenta-
tion and the ease with which the diagnosis can be made
(even based on a short historical account), it may seem
puzzling how CH can remain underdiagnosed, under-
treated and so enigmatic in nature. Accounts of the pre-
dictable attack patterns and how oxygen, almost by
miracle, alleviates the headache have fascinated many,
but true progress in our understanding of the disorder is
lacking.
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CH is a primary headache disorder belonging to the
diagnostic group known as the trigeminal autonomic
cephalalgias (TAC’s) [2]. These headaches share the com-
mon features of short-lasting, severe, strictly unilateral
pain in the distribution of the first division of the trigemi-
nal cranial nerve. Attacks last from 15 to 180 min and
simultaneous activation of the trigeminal autonomic reflex
produces the characteristic cranial, autonomic, accom-
panying symptoms (Table 1) [2]. Systemic manifestations
are also present as patients almost universally become agi-
tated, restless and, as opposed to migraineurs, do not ex-
perience worsening of the pain during movement, perhaps
rather relief. Uniquely, CH patients describe their attacks
to exhibit remarkable circadian and annual periodicity .
The attacks are described to strike at predictable times of
the day and the clusters (bouts) of these at specific times
of the year. However, there is no consensus as no two
studies have ever reached identical conclusions concern-
ing these patterns [3–7].
Diagnostically, CH exists in two forms: an episodic
(ECH) and a chronic variant (CCH), distinguished by
the duration of the attack-free periods [8]. This division
is diagnostic and there is no evidence for a clear reflec-
tion of prognosis, response to treatment or causative
pathology. The social impact of CH is considerable [9]
and it is associated with sizeable direct and indirect eco-
nomic consequences [10]. Consequently, endeavors to
uncover the pathological mechanisms behind this disab-
ling headache have intensified over the past two decades;
regrettably, the challenges associated with investigating
the transient, severe pain attacks accompanied by agita-
tion have slowed progress. Firstly, it is difficult to cap-
ture the attacks and clusters, secondly it may be difficult
for the patients to remain still, complicating measure-
ments. Lastly, provoking the attacks may cause changes
obscuring the findings themselves.
The chronobiological nature of cluster headache
Chronobiology is the study of biological rhythms. In
humans, by far the most noticeable rhythm is the diur-
nal sleep-wake rhythm which roughly follows a 24-h pat-
tern [11]. This, along with a multitude of other changes
in the organism, is evoked by the light and dark periods
of day and night – a consequence of the 24 h. rotation
of the earth around its own axis. These periods and
other Zeitgebers entrain the master circadian clock lo-
cated in the hypothalamic suprachiasmatic nucleus
(SCN) [11]. Through the release of melatonin from the
pineal gland the SCN commands the overall rhythm of
the organism.
CH is arguably the headache disorder which demon-
strates the strongest chronobiological characteristics.
The attacks themselves have been described to be mostly
related to (nocturnal) sleep and to follow specific rhythms
that often provide a high degree of predictability [7, 12].
Nonetheless, numerous unresolved issues in our under-
standing of the pathophysiology and the relation to circa-
dian and sleep-wake regulation remain. The pioneers of
CH chronobiology described the circadian and annual
rhythmicity [5, 6], but it is unclear whether the biphasic
signal of cluster occurrence in ECH is a function of the
solstices, the equinoxes or something else [3, 7]. Further, it
appears that the circadian periodicity may be influenced
by cultural factors but the precise mechanisms remain
obscured [3, 6, 7].
Cluster headache is a sleep-related headache
For reasons which are partly unknown headache and
sleep share an especially close relationship, as evidenced
by a dense anatomical and physiological overlap in the
central nervous system (CNS) [13] but also by a high de-
gree of co-occurrence of sleep problems and headache
[14]. To reflect this interesting, yet poorly understood
interaction, migraine, hypnic headache, chronic paroxys-
mal hemicranias and CH are all classified as “sleep-related
headaches” in the International Classification of Sleep
Disorders [15].
Inspired by anecdotal and clinical experience, sleep
studies in CH have been conducted but results are diver-
ging [12]. Anecdotally, patients awakened by nocturnal
attacks often lucidly recall dreams and typically report
Table 1 Diagnostic criteria for cluster headache according to
the ICHD-2 [2]
Cluster headache
A. At least 5 attacks fulfilling criteria B-D
B. Severe or very severe unilateral orbital, supraorbital and/or temporal
pain lasting 15–180 min if untreated
C. Headache is accompanied by at least one of the following:
1. Ipsilateral conjunctival injection and/or lacrimation
2. Ipsilateral nasal congestion and/or rhinorrhoea
3. Ipsilateral eyelid oedema
4. Ipsilateral forehead and facial sweating
5. Ipsilateral miosis and/or ptosis
6. A sense of restlessness or agitation
D. Attacks have a frequency from one every other day to 8 per day
E. Not attributed to another disorder
Episodic cluster headache
A. Diagnostic criteria A-E for cluster headache
B. At least two cluster periods lasting 7–365 days and separated by
pain-free remission periods of≥ 1 month
Chronic cluster headache
A. Diagnostic criteria A-E for cluster headache
B. Attacks recur over > 1 year without remission periods or with
remission periods lasting < 1 month.
Barloese The Journal of Headache and Pain  (2015) 16:78 Page 2 of 16
that these occur one to two hours after falling asleep.
These sporadic observations have led to the belief that
nocturnal attacks of CH are temporally related to the
rapid-eye-movement (REM) sleep phase, the first of which
typically occurs roughly one hour after sleep onset. The
possible connection with REM-sleep [16–18] and sleep
apnea [17, 19–22] is based on relatively small studies
which are mostly uncontrolled. It appears that while a
temporal association between individual CH attacks and
nocturnal sleep (but not necessarily REM-sleep) is evident,
little is known about the specifics of this link.
Hypocretin - a neuropeptide with a potential role in CH
pathology
A theory of hypothalamic involvement predominates in
CH pathology. The strongest evidence in favor of this
are radiological findings demonstrating specific and ex-
clusive hypothalamic activation during CH attacks [23]
as well as increased hypothalamic grey matter volume in
CH patients [24]. Hypothalamic involvement is further
evidenced by the efficacy of deep brain stimulation (DBS)
of the posterior hypothalamus in medically refractory CH
[25, 26], endocrinological changes (reduced melatonin,
testosterone, noradrenaline among others) [27] and the
chronobiological features of the disorder (rhythmicity of
the attacks and clusters) [28].
Hypocretins (HCRT) 1 and 2 (also known as orexin A
and B) are neuropeptides produced by 10–20,000 neurons
in the lateral and perifornical areas of the hypothalamus
[29]. Caused by the complete loss of HCRT neurons, per-
haps by an autoimmune process, the HCRT concentration
in cerebrospinal fluid (CSF) of patients suffering from nar-
colepsy with cataplexy is low to undetectable [30]. The
HCRT-1 and −2 receptors are G-protein coupled, and
located widely throughout the neuroaxis [31]. HCRT-1
binds to both the HCRT-1 and −2 receptor with equal
affinity whereas HCRT-2 binds to the HCRT-2 receptor
with ten times greater affinity [31]. Crucial for the normal
function of arousal control, sleep regulation, homeostatic
maintenance and possibly pain processing [29], the
HCRTs may be involved in CH pathology by way of a
polymorphism of the HCRT-2 receptor gene [32–35] or
an otherwise related mechanism, possibly involving de-
scending connections from the hypothalamus to brain-
stem circuits involved in trigeminal nociception (Fig. 1).
Systemic manifestations of hypothalamic dysfunction
The aforementioned findings of central involvement
would suggest that systemic manifestations of central
autonomic dysregulation may be present. In CH, ictal in-
volvement of the cranial autonomic nervous system is
undeniable and an inherent feature of the disorder. It is
observable to the surroundings in the form of the ac-
companying symptoms that form part of the diagnostic
criteria. These symptoms result from activation of the
trigeminal autonomic reflex producing hyperfunction of
the parasympathetic division and hypofunction of the
sympathetic [36]. Peripheral stimulation of the pterygo-
palatine ganglion (PG) may induce cluster-like attacks
[37]. Systemically, reports of changes in the electrocar-
diogram (ECG) and ictal bradycardia [38–42] suggest
that general autonomic control is affected in CH. How-
ever, results are contradictory [38, 39, 41–50]. A rela-
tively unobtrusive method for studying the function of
central regulation of the cardiovascular system is by ana-
lysis of heart rate variability (HRV), allowing dissection
of the contributions of the parasympathetic and sympa-
thetic divisions of the ANS. Being a relatively new
method of characterizing autonomic function, studies of
spectral analysis in CH are rare [43, 45].
Hypothesis and aims
A detailed review of the mechanisms and interactions
described above has been published [12] (study I) and it
serves as the pillar-stone for the studies encompassed in
the present thesis. Generally, the thesis is based on a
theory of central pathology as the cause of CH. We
hypothesize that this central pathology revolves around
dysfunction of hypothalamic nuclei, producing condi-
tions in which the painful attacks can arise or perhaps
that these nuclei function as a “cluster generator”. This
gives rise to the characteristic triad of extreme pain in
the first division of the trigeminal nerve with accom-
panying autonomic symptoms, impaired sleep regulation
and chronobiological rhythmicity. This dysregulation
manifests itself as a complex, bidirectional relationship
with sleep involving neuronal circuits in the overlap be-
tween headache pathology and the physiological regula-
tion of sleep, as reviewed in [12]. Thus, the
hypocretinergic system is affected in CH either as an
intrical part of disease mechanisms or as an epiphenom-
enon, reflecting overall hypofunction of hypothalamic
nuclei and descending, antinociceptive projections. It is
also likely that central autonomic control in CH patients
is affected. This may be an essential factor in the trigger-
ing of attacks or may reflect generally altered function of
central autonomic command.
The overall aim of the project was to investigate the
interaction between CH and sleep and the neuro- and
chronobiological features of the disorder. Specifically:
A. To investigate sleep quality, chronotype,
triggers and chronobiological features of
CH in a large population of well characterized
patients [28].
B. To study the macrostructure of sleep as well as
breathing parameters, arousals, periodic limb
movements (PLM’s), limb movements (LM’s) and
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spontaneous CH attacks’ relationship to sleep in
general and specific sleep phenomena [51].
C. To measure the HCRT-1 concentration in CSF from
CH patients during an active bout to investigate
whether levels of HCRT reflects activity of CH [52].
D. To characterize overall autonomic function, as
measured in a head-up tilt-table test (HUTT), in a
population of CH patients during the active bout of
their headache disorder and compare this to
matched, healthy controls [53].
Review
Materials and methods
The data forming the basis of analyses in this thesis was
collected at the Danish Headache Center between winter
2012 and spring 2014. A total of 275 patients and 223
controls in four groups participated in four different
studies (Fig. 2). These were approved under the same
protocol by the ethics committee of the Capital Region
of Denmark (H-2-2012-016) and all patients and
controls gave their written consent in accordance with
the Declaration of Helsinki.
The entire project was composed of two parts (Fig. 2):
A questionnaire and interview-based study aiming to
include as high a number of CH patients as possible
Fig. 2 Study design and patients included in the final analysis at each
stage. Hypocretin was measured in cerebrospinal fluid obtained via
spinal tap. *Control groups were different in all of the investigations.
PSG – polysomnography, MSLT – multi-sleep latency test
Fig. 1 Schematic depiction of the trigeminal-autonomic reflex and related areas. Sensory afferents from cranial structures synapse in the
trigeminal nucleus caudatus. Input is relayed to the brainstem and higher structures including the periaqueductal grey (PAG) and hypothalamus.
Likewise, descending modulatory hypocretinergic connections are received from the hypothalamus. SSN – superior salivatory nucleus, TNC – trigeminal
nucleus caudalis (trigeminal complex), PG – ptyrogopalatine (sphenopalatine) ganglion, TG – trigeminal ganglion. With permission from Holland et al.
2009 (Springer)
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(part 1) and an in-hospital clinical investigation includ-
ing 40 CH patients (part 2). All patients completed the
same questionnaire and interview which also provided
the clinical characterization of the 40 patients participat-
ing in part 2.
Part one: Cross-sectional questionnaire and interview
Patients
Patients diagnosed with ECH or CCH were recruited from
a register of present and former contacts at the Danish
Headache Center. Additionally, a notice was posted in the
newsletter and on the website of the Danish patient
organization for CH. Other headache clinics in Denmark
were contacted and patients receiving treatment at these
clinics were referred to the study if they were interested.
Patients were included if they were between 18 and 65 years
old, had been diagnosed with ECH or CCH (ICHD-II
criteria) and were able to tell CH-attacks apart from other
types of headache. Patients were excluded if they had been
diagnosed with another primary or secondary chronic
headache (≥14 days/month) or did not speak and under-
stand Danish. All patients’ diagnoses were verified by head-
ache specialists at the Danish Headache Center.
Controls
Controls were recruited via notices posted on the internet
and in work places and sport clubs in the Capital Region
of Denmark. Controls were matched for sex and age and
were required to be between 18 and 65 years old and
headache-free (≤1 day of headache/month). They were
excluded if they had severe symptoms of sleep disorders.
Questionnaire
A questionnaire composed of already validated sections
(Pittsburgh Sleep Quality Index (PSQI), Morningness-
Eveningness Questionnaire (MEQ)) and new questions
concerning headache characteristics, life style, impair-
ment and others developed by MB and RJ was sent to
patients and controls. In the final phase of development
the questionnaire was assessed for content and face val-
idity by an expert panel comprised of 10 senior headache
experts (unpublished data). They were asked to evaluate
the questions: Are the instructions clear, is the question-
naire coherent, are the questions relevant, is the ques-
tionnaire logically divided into parts, are the questions
formulated clearly. The questionnaire was also tested
with a randomly selected population of 10 CH patients
representing different ages, sexes and diagnoses (ECH
and CCH) and comments and suggestions were imple-
mented. The paper questionnaire contained 362 questions
in 7 sections: Headache diagnosis, headache burden, treat-
ment, sleep, work, lifestyle habits, and physical activity. It
was estimated that it took the patients roughly one hour
to complete the questionnaire. Following completion of
the questionnaire, answers were verified and ambiguities
ruled out by a structured interview conducted by a phys-
ician or a trained medical student. If the patient or control
invited to participate did not respond within 21 days they
were contacted again by letter and/or telephone and en-
couraged to complete the questionnaire.
The PSQI [54] is a validated [55] 19-item measure of
subjective sleep quality during the past month. The sum
of seven component scores provides a global score, a
higher value reflecting poorer sleep quality. A global score
greater than 5 yields a high sensitivity and specificity in
distinguishing “good and poor sleepers” [54].
The MEQ [56] uses 19 multiple-choice items to chrono-
type patients into five categories: Definite morning, mod-
erate morning, intermediate, moderate evening, definite
evening. The questionnaire has been validated in middle
aged populations [57]. Chronotype reflects at what time of
the day a person is active or inactive, often reduced to
sleeping habits only, i.e. “lark” or “owl”.
To characterize rhythmicity of attacks and clusters,
patients were asked to report the hours of the day or the
months of the year where these were most likely to
occur. They also had the option to report no rhythmi-
city. For further details please see [28].
Part two: In-hospital investigation of sleep, hypocretin
and autonomic function
Forty patients underwent clinical examination, routine
blood sampling, polysomnography (PSG) and multi-sleep
latency test (MSLT). 29 of the patients completed the tilt-
table test and 27 the spinal tap procedure. All investi-
gations were done at Glostrup Hospital, Departments of
Neurology, Neurophysiology and Diagnostics, and at the
Coordinating Research Centre, Dept. of Clinical Physiology
and Nuclear Medicine, Frederiksberg Hospital.
Patients
Patients for part 2 were recruited as described above and
were investigated during the active cycle of the headache
disorder (1–8 attacks/day over the past week) and at
least two weeks into the bout. Exclusion criteria were
other chronic primary or secondary headaches and ser-
ious somatic or psychiatric illness. If patients were on
prophylactic medication this was kept stable for at least
seven days prior to investigation. Patients would attempt
to treat their attacks using oxygen but were allowed to
use other medication such as injectable or nasal triptans,
as a rescue.
Controls
Three separate populations of controls were used:
Sleep investigation For study III 25 controls with an age,
sex and BMI-makeup similar to the patients were included.
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Controls were recruited through www.forsoegsperson.dk,
a website for healthy volunteers, and did not suffer from
chronic headaches, sleep disorders or any other health
problem (one control had mild, controlled hypertension
and hypercholesterolemia) as concluded by interview,
examination and questionnaires. For further details please
see [51].
Hypocretin samples For study IV 27 healthy controls
without headache-, sleep- or other neurological disor-
ders were included from a prior study [58]. Twelve of
the subjects were recruited through advertisement for
healthy volunteers (www.forsoegsperson.dk) and clinical
and neurological examination by a physician was con-
ducted. The remaining 15 subjects were referred for sub-
jective sleep-related complaints but were found healthy by
experienced sleep specialists by interviews, normal clinical
and neurological findings, PSG and MSLT. Controls were
not matched according to age or sex as these factors may
not influence HCRT-levels [59].
Head-up tilt table test For study V 27 controls matched
according to age, sex, BMI were included. All controls
were interviewed to ensure they were healthy and did not
suffer from disorders including primary headaches. For
further details please see [53].
Methods
Polysomnographic recordings
Recordings took place during admission at the Danish
Center for Sleep Medicine and Department of Neurology
at Glostrup Hospital, Denmark. PSG recordings were
performed and scored in accordance with the AASM
standard [15]. Final assessment and possible sleep dis-
order diagnoses were made by senior doctors, special-
izing in sleep medicine according to the ICSD-2 [15].
Two nights of PSG-recordings were made for patients
and one night for controls. MSLT was done after the
last night of sleep recording. Additionally, for detailed
methods please see [51].
Measurement of cerebrospinal fluid hypocretin-1
10 mL CSF was collected by the spinal tap procedure in
the attack-free state between 08.00 and 12:00. Hypocretin-
1 was analyzed in crude CSF by radioimmunoassay from
Phoenix Pharmaceuticals (Belmont, CA, USA). We used
the same methodology as in a previous study [58]. Assay
quality was monitored by the internal positive control
sample included in the assay kit. Previously used group-
ings of CSF intervals for HCRT-1 concentrations (low
(≤110 pg/ml), intermediate (>110 ≤ 200 pg/ml), and nor-
mal (>200 pg/ml)) were not strictly applied in this sample
as these are most relevant in the diagnosis of narcolepsy
[30, 60, 61]. For detailed methods please see [52].
Head-up tilt table test
All tests were performed in the fasting state between
08.00 and 14.00 h. at standard room temperature. After
10 min. of supine rest, baseline data were acquired during
a further 10 min. of rest, where the subjects refrained from
speaking and from unnecessary movements. The subjects
were then loosely strapped to an electrically driven tilt
table and tilted to a 60° head-up position (HUT) within
10 s. and stayed in this position for at least 10 min.
if intolerable symptoms did not appear. RR-intervals
and blood pressure (BP) were measured continuously
from a bipolar 2-channel ECG and by Finometer equip-
ment (Finapres Medical Systems BV, Amsterdam, The
Netherlands), respectively. Baseline values of HR, SBP and
diastolic blood pressure (DBP) were calculated as mean
values from the 30 s. preceding tilt in the supine pos-
ition and during 30 s. obtained in the 5th and 10th
min. of HUT. Analysis of HRV was performed according to
current guidelines [62] using share-ware (Kubios, vers.
2.0, kubios.uef.fi). For detailed methods please see
[53].
Data and statistics
Characterization of the patients for all four studies was
based on the questionnaire and interview. A CH index
was calculated by the following equation: Attacks per
day x hours per attack x days per cluster x clusters per
year and is a measure of the total time/year that the pa-
tient has cluster headache. In this specific calculation,
for CCH patients, number of clusters/year was set at
one and cluster duration was set at 365 days. The motiv-
ation for calculating this index is to provide a single
number which reflects the amount of headache, as this
is sometimes not completely clear, taking into consider-
ation clusters, cluster duration, attacks and attack dur-
ation. Further, we wanted to characterize the patients
beyond the dichotomy of episodic-chronic as some epi-
sodic patients in fact may experience far more headache
than some chronic.
Apart from diagnosis (ECH, CCH) and sex, the
patients were stratified based on self-reported character-
istics including: “Annual rhythmicity” – clusters occur at
the same time each year, “diurnal rhythmicity” – attacks
occur at the same time each day, “sleep attacks mostly” –
the patient reports that the majority of attacks occur dur-
ing sleep, “sleep and awake or mostly awake” – the patient
reports no predominance of attacks during sleep, attacks
during PSG monitoring and whether the patients primar-
ily suffered attacks during sleep or both during sleep and
wake. The data gathered in the questionnaire and
interview study allowed for even finer distinction of
patients and an analysis of the exact times patients
reported attacks was made: 08.00-21.00, 22.00-07.00. BMI
was calculated from self-reported height and weight
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(BMI = kg/m2). Tobacco “pack-years” was calculated
as no. of cigarettes (or equivalent) smoked daily/20 x no.
of years smoking.
SAS 9.3 or 9.4 was used for all statistical analyses.
P < 0.05 was considered statistically significant. Levene’s
test for homogeneity was used to check variance. T-test
was used to compare two groups and ANOVA for com-
parison between more than two groups. Bonferroni cor-
rections were applied in the analysis of PSQI and in the
comparison of diagnostic subgroups in HCRT-analysis.
Chi-square test was used to calculate differences in sex
composition, smoking status, MEQ-groups, laterality and
prevalence of sleep apnea. Linear regression was used to
describe the association between daylight hours and cluster
occurrence and the CH index and PSQI. The Wilcoxon
rank sums test was used for non-parametric data.
In the analysis of PSG data, the first PSG in patients
and controls were compared using unpaired statistics.
All comparisons between patients and controls only
used the first night of data for patients to ensure that
data was comparable. For consistency, the patients’ first
and second night of recording were compared with
paired statistics.
In the analysis of HUT data, HR and BP and changes
in the time domain were analyzed as changes in percent
to account for baseline values.
Results
Questionnaire: sleep and chronobiology
Response rate and clinical characteristics
The response rate for both patients (57.2 %) and con-
trols (54.5 %) was within accepted and expected ranges
[14]. 275 patients and 145 age and sex-matched controls
completed the questionnaire and interview (Table 2).
For further details please see [28].
While the primary focus of the study was to investi-
gate chronobiological features, some findings were of a
more clinical nature. As expected, on average, chronic
patients scored 7-fold higher on the CH-index (935.6 ±
890.2) compared to episodic (135.6 ± 204.4). This is a
considerable difference and it should be noted that there
is a huge span and some ECH patients in fact scored
very highly (Range: ECH = 0.35-1428, CCH = 60-5096).
Interestingly, a difference between these two groups in
attack duration with treatment was found, CCH patients
suffering longer attacks (44 vs. 32 min., P = 0.0052).
Chronobiology
As expected far more ECH patients than CCH reported
annual rhythmicity (65.2 % vs. 36.4 %, P < 0.0001) [28].
However, while there was a difference in the prevalence
of annual rhythmicity, there was no difference in the
prevalence of circadian rhythmicity between the two pa-
tient groups (ECH: 83.4 % vs. CCH: 79.5 %, P = 0.4332).
Interestingly, we also found that patients exhibiting one
type of rhythmicity were more likely to exhibit the other.
Eighty percent of patients reported that nocturnal
sleep (as opposed to napping) was an attack trigger. Only
1/3 of patients reported that napping triggered attacks. Pa-
tients with diurnal rhythmicity more frequently reported
sleep as a trigger compared to patients without diurnal
rhythmicity (P < 0.0001).
Characteristic patterns were discovered in the analysis
of attack incidence during the 24 h. of the day. By far
the most reported time for nocturnal attacks was 02.00 h.
During the day, the most frequently reported time for at-
tacks was 16.00 h. Three low points, roughly coinciding
with meal times, are noted – 09.00, 12.00 and 18.00. From
18.00 and onwards attack incidence climbs steadily to-
wards its peak at 02.00.
Looking at annual cluster incidence (or worsening of
attacks for CCH) a clear pattern of betterment during
the late spring – summer – early autumn was identified.
A regression analysis comparing cluster incidence and
daylight hours was highly significant (P = 0.0002).
Sleep quality
Patients scored significantly higher on the PSQI (8.4 vs.
4.0, P < 0.0001) compared to controls indicating a poorer
subjective sleep quality [28]. A negative relationship
between time passed since last attacks and PSQI score
was identified (P < 0.0001). However, even one year after
patients suffered their last attack, PSQI remained above
the pathological cut-off at 5. In a subgroup analysis the
same trend was identified in the following groupings:
 Patients reporting sleep as a trigger (n = 220).
 Patients reporting no sleep-trigger (n = 55).
 Patients reporting exclusively attacks between
22.00-07.00 (N = 72).
 Patients reporting attacks during all 24 h of the day
(but not exclusively 22.00-07.00) (N = 203).
 Patients reporting exclusively daytime attacks
(08.00-21.00) (N = 18). Overall these patients still




Forty patients and 25 age- and sex-matched controls
contributed a total of 99 nights for analysis (Table 3).
Table 2 Demographics for patients in the questionnaire study.
N Diagnosis Age yrs Sex, %M BMI
Patients 275 187E/88C 47.9 (11.1) 69.5 25.5* (4.2)
Controls 145 46.9 (12.9) 69.7 24.5* (3.5)
Data are expressed as means (SD). *P < 0.05. E – episodic, C – chronic
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Findings included lower REM-density (17.3 vs. 23.0 %,
P = 0.0037) and latency (2.0 vs. 1.2 h., P = 0.0012) in
patients compared to controls [51]. Apart from the
affected REM-sleep, macrostructurally there was no
difference between patients and controls except for
lower efficiency (77 vs. 87 %, P = 0.0026) and longer sleep
latency (0.56 vs. 0.18 h, P = 0.0057). There was no tem-
poral association between REM-sleep, any other sleep
stage or particular sleep-related events, including apneas
and desaturations and observed, spontaneous nocturnal
attacks (N = 45). Furthermore, patients had far fewer
arousals (7.3 vs. 14.1, P = 0.0030). As opposed to all previ-
ous studies no difference in prevalence of sleep apnea in
patients vs. matched controls (38 vs. 34 %, P = 0.64) was
identified. However, average AHI in patients was numeric-
ally higher (AHI 10.75 vs. 4.93).
In one patient a striking rhythmicity of nocturnal at-
tacks was noticed (Fig. 3). This patient suffered a total of
nine attacks during the two nights of recording. There
was no relation with any particular sleep stage, rather
the attacks occurred roughly every 90 min. During night
1, at 02.00, the patient wakes up but without an attack.
Hypocretin
In total 26 patient and 27 control samples of CSF were
included in the HCRT-1 analysis (Table 3). A highly
significant reduction of HCRT-1 levels in patients
compared to controls was identified (382 vs. 431 pg/ml,
P = 0.0004) [52]. Both subgroups of CH patients (ECH
(375 pg/ml, P = 0.0005) and CCH (389 pg/ml, P = 0.0221))
were significantly reduced compared to controls (Fig. 4).
There was no difference between the two subgroups of
patients. However, on average, CCH patients had higher
concentrations and the range and standard deviation was
greater (CCH: 291-480 ± 60 vs. ECH: 312-426 ± 38). There
were no significant differences in HCRT-1 concentrations
Table 3 Clinical characteristics. Attack duration is for treated attacks. Bout duration and bouts/year only includes ECH







PSG & MSLT Patients 40 21E 19C 73 44.2 (11.2) 25.7 (4.0) 11.2 (7.4) 35.0 (33.1) 4.6 (1.9) 12.3 (20.3) 1.7 (1.1)
Controls 25 64 47.6 (12.1) 24.2 (3.4)
HCRT Patients 26 14E 12C 66 44.3 (11.5) 24.9 (3.8) 10.3 (5.9) 27.2 (18.2) 4.3 (1.8) 14.2 (8.8) 1.6 (0.9)
Controls 27 44 32.4 (9.5)
HUT Patients 27 14E 13C 70 44.9 (11.3) 25.4 (3.8) 11.3 (7.8) 37.2 (37.8) 4.4 (1.8) 12.7 (9.2) 1.7 (1.2)
Controls 27 70 49.0 (8.3) 24.4 (2.7)
Data is presented as means (SD). PSG – polysomnography, MSLT – multi-sleep latency test, HCRT – hypocretin, HUT – head-up tilt table test, E – episodic, C – chronic
Fig. 3 Hypnograms from night 1 (top) and 2 (bottom) from a patient suffering nine spontaneous CH attacks (arrows) during recordings. As is
seen, the attacks occur in stages W, REM, N2 and N3 at remarkably regular intervals. With permission from Barloese et al. 2014 (Wiley) [51]
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between patients dichotomized according to rhythmicity
and sleep attacks.
Autonomic function
There were no differences between patients and controls
in standard cardiovascular responses to tilt including HR
and BP. However, patients did present a higher BP
throughout the test (Patients: 121–128/79–88 mmHg,
controls: 107–115/56–68 mmHg, p < 0.01–0.0001) [63].
In both the non-linear and frequency domain analyses,
patients presented a blunted response to tilt. These dif-
ferences were significant in the analysis of normalized
units (HF n.u. and LF n.u.) and the LF/HF ratio as well
as the SD1/SD2 ratio. Within the CH population there
were no differences when dichotomizing according to
subdiagnosis, rhythmicity and sleep- or sleep and wake
attacks [63].
Discussion
In the investigations made over the past 30 years several
theories about sleep and nocturnal CH attacks have been
proposed including a strictly temporal connection with
the REM phase of sleep [17, 64] and association between
sleep apnea and CH [65]. While some case reports may
seem to provide evidence of such a direct, causal rela-
tionships [66–68], it is likely that the interaction be-
tween sleep and CH is more complex, multifaceted and
indirect in nature.
Cluster headache is a chronobiological disorder
Cluster headache provides a unique opportunity to study
a disorder which is present at very specific times of the
year and then spontaneously remits and is, at least with
regards to the headache, completely absent for long
periods. Few other disorders show this kind of strong
chronobiological features, and those that do have some
interesting similarities with CH, such as the rare lithium
responsive [69], recurrent hypersomnia Kleine-Levin
syndrome [70]. While it is obvious and easy to establish
that the headache attacks completely remit outside of
the cluster period in the episodic subforms, it is un-
known whether underlying pathology remains present,
perhaps manifesting in unknown ways.
The present results suggest that there may be a long-
lived dysfunction present, which the majority of the time
manifests as poor sleep quality and at specific times of
the year perhaps when entrainment by natural light
cues is weaker, results in periodic disinhibition of the
trigeminal autonomic reflex. The anatomical substrate
for this interaction may be the complex brainstem
and hypothalamic circuits where an overlap between
headache and sleep exists [13]. In susceptible individ-
uals, at times of the year when Zeitgebers change or
are weaker, resultant cluster penetration may involve
melatonin metabolism. Melatonin concentrations have
been shown to be lowered and to exhibit a blunted
nocturnal peak in CH patients regardless of cluster
presence [71–74], and when administered prophylac-
tically it may have a slight, positive effect on the clus-
ters [75]. The strong association between cluster
occurrence and the amount of daylight demonstrated
in this study further strengthens a hypothesis of an
intricate relationship between melatonin metabolism
and CH. A possible connection with testosterone has
Fig. 4 Hypocretin-1 levels in patients and controls. ECH – episodic cluster headache, CCH – chronic cluster headache, CTRL – control, HCRT-1 –
hypocretin 1
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also been suggested which may be especially interest-
ing considering REM-sleep’s effect on this hormone
[76] and recent findings suggesting it may positively
affect antinociceptive signaling in the trigeminal com-
plex [77].
A PSQI score above 5 gives a high sensitivity and spe-
cificity in distinguishing “good and poor sleepers” [54].
In the results presented here, sleep quality improves as
time passes since the last attack but remains abnormal
even one year after the last attack, implying a permanent
or long-lived dysfunction in sleep regulatory mecha-
nisms. It also means that it is not only the nocturnal
attacks themselves that in a direct manner disturb the
sleep of CH patients, since sleep quality remains poor
even in the attack-free state. This is further evidenced by
the fact that the 18 patients reporting exclusively day-
time attacks also reported poor sleep quality. Subjective
sleep quality may thus be an indirect measure of the
presence of an underlying pathological mechanism, and
should be investigated further. A systematic, detailed re-
cording of sleep history may be useful in the clinical
evaluation of patients and sleep quality could be used to
evaluate this sub-threshold presence of the cluster.
The classification of patients as episodic or chronic
presents some problems unique to CH. For example,
current diagnostic criteria [2, 8] do not specify whether
the patient should be completely off preventive medica-
tion to be classified as episodic. Further, many patients
classified as episodic may be significantly more affected
by the headache than some patients fulfilling the criteria
for chronic CH. For research purposes, it seems that the
usefulness of dichotomizing according to subdiagnosis
may not be universal. These arguments were the main
reason for the development of the CH-index which re-
flects the total time the patient has suffered from head-
ache over the past year. As can be seen, the range is
huge and there is a significant overlap between ECH and
CCH. Although the calculation is subject to recall bias,
the index still provides one number reflecting the
amount of headache the patient has, taking into account
attack frequency, attack duration and cluster duration.
When based on prospective recordings the index may
precisely and in a comparable manner reflect total head-
ache burden.
A complex, bi-directional relationship with REM-sleep
The connection between CH and REM-sleep is the sub-
ject of a long-running debate. Early studies indicated a
temporal relationship which was supported by observa-
tions that CH attacks typically occur 60–90 min. after
falling asleep, coinciding with the first REM phase. Sev-
eral reports, including the present results, now show
that there is no relation with REM-sleep for any of the
subdiagnoses [78, 79]. However, it is clear that REM-
sleep is affected in CH patients but the cause remains
unclear. Firstly, it must be taken into consideration that
the homeostatic pressure for sleep and REM-sleep is
most likely affected in this patient group as a result of
nocturnal awakenings. Secondly, considering the de-
scribed overlap of sleep and headache, it seems likely
that changes in hypothalamic and brainstem nuclei may
directly or indirectly affect REM sleep. The ventrolateral
grey and lateral pontine tegmentum, receives hypocre-
tinergic input, and may be an area of interest in this
regard [13]. Further, in the present results there was no
difference in the macrostructural composition of sleep
between patients and controls apart from a lower REM
density. Serotonergic and noradrenergic activity leads to
suppression of REM sleep [80, 81] and the noradrenergic
locus coeruleus and the serotonergic dorsal raphe nu-
cleus are areas of direct anatomical overlap between
sleep regulation and headache [13]. With this in mind,
the challenge is to dissect the contributions from a
change in homeostatic pressure and a change in function
of the hypothalamic and brainstem nuclei involved in
the regulation of sleep and pathology of headache. At
present, our understanding of these circuits and interac-
tions is not sufficient to make precise conclusions. A
single case report hints at a fascinating change in sleep
patterns taking place before the cluster [82]. This find-
ing, and the fact that subjective sleep quality is worse
even outside of clusters in ECH patients suggests that
CH is a syndrome in which changes first manifest as
dysregulation of sleep and secondly as a destabilization
of trigeminal nociceptive processing.
Sleep disordered breathing is a common finding in men
Up to 24 % of middle-aged males exhibit sleep disor-
dered breathing (AHI ≥ 5) [83] and the studies suggest-
ing an increased prevalence of sleep apnea in CH are
uncontrolled [17, 20, 22] except two [19, 65]. Further, in
earlier studies it is not always clear whether patients
were in active bout during investigation and one study
investigating the same patients inside and outside of
bout does not specify how many patients were investi-
gated outside of bout and for how long the patients had
been attack-free [65]. All the patients included in the
present study [51] were in active bout and we did not
find a significant difference between prevalence of sleep
apnea in patients compared with controls. However, pa-
tients did present more severe cases and a numerically
higher apnea-hypopnea index (AHI), but it is entirely
conceivable that this may have been caused by the
massive over-representation of smokers in the patient
group. Our patients were only investigated during the
active part of the disorder and the possibility that
hypothalamic dysregulation produces sleep apnea dur-
ing the cluster period cannot be excluded. However,
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it seems unlikely that the apnea event itself is the
trigger of nocturnal CH attacks, as no connection be-
tween the apnea events and nocturnal attacks were
identified. Further anecdotal evidence provides no in-
dication that treatment of the apnea alleviates the head-
aches [51, 65].
Fewer arousals is a common finding in headache disorders
The role arousals play in healthy sleep is not completely
clear but by definition they signify cortical activation. It
has been suggested that they ensure the reversibility of
the sleep stage and connect the sleeper with the (dangers
of the) outside world [84]. They may represent a disrupt-
ing feature of sleep but may also be necessary for nor-
mal, healthy sleep and are associated with autonomic
activation [84]. They are the result of changes in activat-
ing systems located in lower brain centers and the find-
ing of reduced arousals – hypoarousal – in CH patients
suggests reduced activity of ascending projections from
the thalamus, hypothalamus and brainstem to the cor-
tex. Hypoarousal has been identified before in other
headache diagnoses [85–90] but the significance re-
mains unknown. In the present study it is particularly
surprising that the patients have fewer arousals, since
they, in parallel with this finding, present with a
higher AHI, traditionally associated with a tendency
towards a higher number of (pathological) arousals.
As with sleep in general, arousals may be affected by
homeostatic pressure, and in this patient group it is
unknown which role is played by underlying patho-
physiological mechanisms and the direct influence of
nocturnal CH attacks.
Reduced hypocretin and trigeminal pain processing
Investigation into the physiological actions of HCRT is
an area of active research, there are many unknowns and
a discussion hereof remains somewhat hypothetical. It
has, however, become clear that the phenotype exhib-
ited in narcolepsy with cataplexy, brought about by a
complete loss of hypocretinergic signaling, does not
reveal all of HCRT’s functions. HCRT modulates the
function of dopaminergic, histaminergic, noradrener-
gic and serotonergic neurons [91–93] in a complex
manner and project widely in the CNS including to
the LC, raphe nuclei, hypothalamic nuclei, spinally to
the dorsal and ventral horns, to motor nuclei and
limbic regions as well as the neocortex [94]. The dra-
matic effect of the complete loss of hypocretinergic
signaling demonstrated in narcolepsy with cataplexy
has given rise to a theory of a switching or gating
function of HCRT in neuronal, including trigeminal,
processing [93]. That HCRT plays a role in the modula-
tion of trigeminal pain processing is supported by four
lines of evidence:
1. Studies show an increased prevalence of migraine in
narcolepsy patients [95, 96]. Further, the fact that
dual HCRT antagonists frequently produce headache
(although not migraine or CH-like pain) as a side
effect [97, 98] have provided indirect evidence that
hypofunction of HCRT signaling may destabilize
trigeminal nociceptive processing resulting in
headache.
2. Animal studies demonstrate that administered
HCRT-1 produces anti-nociceptive results and
HCRT-2 pro-nociceptive results [99]. Further, rats
treated systemically with HCRT-1 have inhibited
nociceptive responses of TNC neurons in response
to electrical stimulation of the dura mater [100].
3. The HCRT-1 concentration has been shown to be
increased in MOH and chronic migraine compared
with healthy controls [101]. In CH, we found
decreased levels of HCRT-1 (but within normal
levels) which is in agreement with a prior small
study which found numerically decreased levels in
ECH but not CCH [102].
4. Genetic studies implicate the HCRT-system in
CH; studies show that a particular polymorphism in
the HCRT-2 receptor gene may increase the risk of
CH [32, 34, 103], although not entirely consistently
[35, 104].
Thus, clinical and animal studies suggest that HCRT
may indeed play a fundamental role in the way the CNS
processes pain, particularly cranial nociception. Whether
the observed reduced levels of HCRT-1 levels in the CSF
of CH patients truly reflects a hypofunction of hypothal-
amic descending antinociceptive signaling, or is simply
an epiphenomenon, perhaps reflecting overall hypothal-
amic hypofunction, remains to be elucidated in future
studies. HCRT-1 concentrations may be influenced by
sleep macrostructure [105, 106] so mechanisms may be
complex. However, as with testosterone, it is possible
that this diminished release somehow alters pain-
thresholds in the trigeminal complex. Further, hypocreti-
nergic input to nuclei involved in autonomic control may
be particularly interesting in this regard [107].
Is autonomic dysregulation a purely local affair?
The cranial autonomic symptoms of CH are caused by
an increase in parasympathetic outflow from the super-
ior salivatory nucleus. This produces symptoms such as
lacrimation and rhinorrhea. Dilatation of the internal ca-
rotid artery results in compression of the oculomotor
nerve producing diminished sympathetic innervation
resulting in ptosis and miosis. The different manifesta-
tions of these symptoms in CH patients most likely re-
flect a highly variant facial anatomy. While activation of
the trigeminal autonomic reflex is undeniable, it is still
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unknown what triggers this activation. Additionally, in-
volvement of systemic autonomic control in CH is the
subject of debate. Based on previous observations, it is
likely that central mechanisms involved in CH-pathology
influence, or are influenced by, a dysfunction of auto-
nomic control. One observational study showed that as
many as 71 % of daytime attacks occur during physical
relaxation [108] - a time of parasympathetic dominance.
A few studies specifically investigating cardiovascular re-
sponses to various challenges in CH patients seem to
indicate increased activity of the parasympathetic system
[38, 48] although not entirely consistently [44, 45].
In the present results, significant changes in the HRV
spectral and non-linear analysis of the response to tilt
were found during HUT. The changes found would sug-
gest a blunted sympathoexcitatory response to the
change from supine to standing position. In the setting
of (posterior) hypothalamic dysregulation, evidenced by
radiological [23], endocrinological [27] and the present
clinical findings of rhythmicity, dysregulation of the cen-
tral hub of autonomic control located here (dorsomedial
and paraventricular nucleus) [109], agrees with current
theories of a central pathological mechanism. A previous
study found an increased sympathoexcitatory drive dur-
ing HUT in eight CCH patients after implantation of a
DBS system [43]. Further, decreased levels of noradren-
aline has been found in CH and could be related to clin-
ical features [110].
Consequently, a pertinent question remains whether
the observed blunted sympathoexcitatory response is an
epiphenomenon of general hypofunction of hypothal-
amic nuclei, or if it reflects a fundamental pathological
process. It has been theorized that diminished sympathetic
drive may explain other findings in CH such as lower
melatonin [73, 74, 111], lower testosterone [112–114],
increased cortisol [115] (reviewed in [27]) and why ma-
nipulation of this axis with prednisone is effective in CH
but not in other primary headache disorders [116]. Such a
theory would need to address the unique features of CH
in comparison to other primary headaches. However,
findings of both sympathetic and parasympathetic
hypo- and hyperfunction in migraine may be contradict-
ory [117–120]. No consensus exists in migraine and
different methods and inherent differences between
migraineurs and CH patients (age, sex, smoking habits)
make the comparison complex.
Interestingly, patients suffering from narcolepsy with
cataplexy, who are completely HCRT-deficient, do not
respond to tilt with an increase in LFnu, a decrease in
HFnu, and increased LF/HF as do normal controls [121].
This suggests that HCRT may be necessary for the
increase in sympathetic tone necessary for a transition
to sympathodominant balance of autonomic tone after
tilt, and may suggest a connection between the present
findings of a weakened sympathodominant response to
HUTT and reduced HCRT-1 levels. Speculatively, in
CH-predisposed individuals, physiological changes in
autonomic tone may contribute to disinhibition of noci-
ceptive processing in the TNC in turn resulting in unre-
strained activation of the trigeminal autonomic reflex.
Methodological considerations
The present studies present data from the largest, best-
characterized population of CH patients with specialist-
verified diagnoses. The data is of a high quality and
proven and validated methods were applied. By contact-
ing the patients personally a high degree of precision
could be obtained and ambiguities resolved. It is further
strengthened by the fact that several investigations were
carried out in the same population. We used a novel
way of characterizing the total headache load by means
of an index, as the current diagnostic criteria have some
shortcomings. The clinical investigations were conducted
in-hospital which provided ideal conditions for observation.
CH presents some unique challenges when it comes to
studying the attacks. Because of the extreme pain and
ethical considerations both acute and preventive medica-
tions were allowed during the investigations. In the three
clinical studies analyses were conducted to identify a
possible influence of this on results, but none was found.
Nevertheless, it cannot be ruled out that it may have af-
fected results. Further, it was noticed that the patients
suffered noticeably fewer attacks while admitted. This is
an interesting finding, as it implies that the increased
sympathetic tone associated with a stay in new sur-
roundings may affect the generation of cluster attacks.
The investigators had expected this to a certain degree
and allowed for ample time for the patient to familiarize
him- or herself with the department. Further, the patient
stayed in a quiet, single room with television and internet
access and PSG was conducted on two nights to allow the
patient to become accustomed. For more detailed meth-
odological considerations please see [28, 51, 52, 63].
Conclusions
Overall the present results support a causative role or
very intricate involvement of central mechanisms in the
pathogenesis of CH. However, due to the complex inter-
actions and overlap of anatomy and physiology, there is
considerable difficulty associated with determining the
contributions of structures involved. It may be possible
that some of the observed changes are epiphenomena
reflecting other central processes of brainstem and hypo-
thalamic circuits.
It is tantalizing to theorize that the changes in the auto-
nomic system and hypocretinergic signaling contribute to
the stereotypical presentation of the CH patient. At the
root of these mechanisms lie changes in hypothalamic and
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brainstem nuclei which are detrimental to the normal
regulation of sleep, headache or no headache. In the set-
ting of a weakened entrainment of the biological clock,
and dysregulation of the posterior hypothalamus, the
balance of nociceptive and antinociceptive input to the
trigeminal nucleus is dysregulated, resulting in disinhib-
ition of the trigeminal autonomic reflex: A downward,
self-perpetuating spiral of pain and activation of the auto-
nomic reflex. As the reflex runs its course, and is eventu-
ally exhausted, the patient is left for want of pain relief,
living in constant fear of when the next attack will arise.
As the illustrious Nicolaes Tulp noticed several hundred
years ago: The unfathomable pain and predictability
of the CH attacks become an inseparable part of the
patients’ lives.
Future perspectives
Future endeavors in CH research should focus on the
following aspects of the disorder:
1. Prospective investigations of sleep and
chronobiology in CH patients in the time
leading up to a cluster may provide valuable insight
into the changes taking place. It is possible that
changes in hypothalamic nuclei manifest themselves
before the breakthrough of cluster attacks, possibly
as changes in sleep regulation.
2. Further investigation of specific sleep-related
phenomena may provide insight into the
mechanisms affected in CH, especially the
investigation of sleep outside of the cluster. Careful
attention should be paid to how much time has
passed since the last attack, i.e. how far outside of
the cluster the patient actually is.
3. Manipulation of the trigeminal autonomic reflex is a
promising therapeutic target. It is possible that
feedback mechanisms may influence the function of
brainstem nuclei and this interaction should be
investigated.
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